	US 11,865,082 B2
	Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
Laura Codarri Deak, Schlieren (CH); Douglas Hanahan, Saint-Sulpice (CH); Christian Klein, Schlieren (CH); Valeria Nicolini, Schlieren (CH); Pablo Umana, Schlieren (CH); and Stephan Wullschleger, Urdorf (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffman-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 1, 2021, as Appl. No. 17/464,518.
Claims priority of provisional application 63/076,020, filed on Sep. 9, 2020.
Prior Publication US 2022/0072103 A1, Mar. 10, 2022
Int. Cl. A61K 38/20 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 35/15 (2015.01); A61K 38/17 (2006.01)

CPC A61K 38/2013 (2013.01) [A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)]

21 Claims

1. A therapeutic method of treating cancer comprising administering to a subject a combination therapy comprising (a) a programmed death 1 polypeptide (PD-1)-targeted interleukin 2 (IL-2) variant immunocytokine in combination with (b) an antibody which binds to human programmed death ligand 1 (PD-L1),

wherein the PD-1-targeted IL-2 variant immunocytokine comprises:

i) a heavy chain variable domain VH of SEQ ID NO: 5 and a light chain variable domain VL of SEQ ID NO: 6, and the polypeptide sequence of SEQ ID NO: 2, or

ii) the polypeptide sequences of SEQ ID NO: 7, and SEQ ID NO: 8 and SEQ ID NO: 9, or

iii) the polypeptide sequences of SEQ ID NO: 12, and SEQ ID NO: 13 and SEQ ID NO: 14, and wherein the antibody which binds to human PD-L1 comprises

a heavy chain variable domain VH of SEQ ID NO: 19 and a light chain variable domain VL of SEQ ID NO: 20.